Peptides represent a billion-dollar market in the pharmaceutical industry, but they can generally only be taken as injections to avoid degradation by stomach enzymes. Scientists at EPFL have now developed a method to generate peptides that resist enzymatic degradation and can be taken orally.
Peptides are short chains of amino acids that occur in our body, in plants or bacteria to control diverse functions. Several peptides are used as drugs such as insulin, which controls the metabolism of sugar, and cyclosporine, which suppresses organ rejection after transplants. More than 40 peptides are already approved as drugs, generating revenues in the billions. There are several hundreds of peptide-based medications currently in clinical trials.
But almost none of these drug-peptides can be taken orally. Since peptides are an important part of food, the stomach and intestines harbor countless enzymes that can degrade them, meaning that most peptide-based medication do not survive the passage through the gastrointestinal tract.
Hope to generate more stable peptides came from “cyclic” peptides, whose ends are joined together by chemical bridges making them more stable than linear ones because their backbones are less flexible and thus harder to attack by enzymes. In 2018, the research group of Christian Heinis at EPFL developed a peptide format termed double-bridged peptides, where peptides are cyclized by two chemical bridges that provide even higher stability. Despite its success, most such peptides were not sufficiently stable to survive the enormous enzymatic pressure found in the gastrointestinal tract.
Now, Heinis’s group has developed a new method that identifies among billions of double-bridged peptides those that bind a disease target of interest and survive enzymes of the gastrointestinal tract. The method is published in Nature Biomedical Engineering, and involves three steps.
First, billions of genetically encoded random peptide sequences are cyclized by two chemical bridges that impose conformational constraints onto the peptides’ backbones so that they are more difficult to attack by enzymes.
Second, this library of peptides is exposed to enzymes from cow intestine to eliminate all those peptides that are not stable.
In the third and last step, the scientist dip target proteins into the pool of surviving peptides to fish out those that bind to the wanted disease target. “It’s a bit like searching a needle in a haystack, and this method makes this easy,” says Heinis.
With this method, the researchers have succeeded for the first time in evolving target-specific peptides that can resist breakdown in the gastrointestinal tract. For example, they gave mice a lead peptide that inhibits thrombin – an important anti-thrombosis target – in the form of a pill. The peptide remained intact in the stomach and intestines, and even though it reached the blood stream in rather small quantities, most of it remained fully intact across the entire gastrointestinal tract. This is a key step towards engineering oral peptide drugs.
Heinis’s group is now applying the new method to develop oral peptides that act directly on gastrointestinal targets, meaning that they don’t need to travel into the blood stream. “We are focusing on chronic inflammatory diseases of the gastrointestinal tract like Crohn’s disease and ulcerative colitis as well as bacterial infections,” says Heinis. “We have already succeeded in generating enzyme-resistant peptides against the interleukin-23 receptor, an important target of these diseases, which affect millions of patients worldwide without any oral drug available.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Nuritas Artificial Intelligence Discovers Plant-Sourced Peptides with Dramatic Effects on Muscle Strength and Recovery
Second PeptiStrong™ trial may offer the most effective solution ever discovered for muscle health NEW HAVEN, Conn., March 21, 2023 /PRNewswire/ ...
- Peptide Therapeutics Market is CAGR of 10.8% over the period of 2023 to 2033
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI), the worldwide peptide therapeutics market currently for peptide therapies is estimated to be worth ...
- FDA Approves Zavzpret, a New Fast-Acting Nasal Spray to Treat Migraine
The Food and Drug Administration (FDA) approved Zavzpret, a new nasal spray for the treatment of migraine, last week. The medication is expected to be available for patients beginning in July.
- Investigating the effects of amide-to-ester substitutions on membrane permeability of cyclic peptides
The utilization of substitutions shown in a new study can be used to develop cyclic peptides with high membrane permeability and oral bioavailability for clinical and therapeutic applications.
- Opioid research: How scientists are using peptides to try to build a safer drug
By analyzing the connections between these receptors and their natural peptide partners, the researchers hope to inspire the development of peptide-based or peptide-inspired medications with fewer ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”oral peptides” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- We wouldn't have Ozempic without Gila monsters — their hunger-regulating venom inspired weight-loss drugs
Ozempic was created thanks to research on Gila monsters, the only venomous lizard in the US. Their venom slows digestion and curbs cravings for hours.
- PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate
The development candidate arising from the strategic partnership with RayzeBio is a novel macrocyclic peptide-RI conjugate against Glypican-3.
- Gyros Protein Technologies introduces new PurePep EasyClean services to accelerate development and manufacturing of peptide-based drugs
Gyros Protein Technologies AB today announced the launch of three service offerings to support development and manufacturing of peptide-based drugs.
- Eating certain foods may do the same thing as Ozempic and related drugs — without the side-effects
Ozempic (and the similar drug Wegovy) has had more than its fair share of headlines and controversies. A global supply shortage, tweets about using it from Elon Musk, approval for adolescent weight ...
- Altimmune Stock Is Diving: What's Going On?
Shares of clinical-stage biopharmaceutical company Altimmune Inc (NASDAQ: ALT) are trading lower Tuesday after the company announced results from an interim analysis of ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”peptide-based medications” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]